



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 478 101 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91250255.6

(51) Int. Cl.5: C07K 7/00, A61K 37/02,
C12P 21/00, G01N 33/53,
G01N 33/574, A61K 39/395

(22) Date of filing: 20.09.91

(30) Priority: 24.09.90 US 587197
13.09.91 US 757037

(72) Inventor: Eyal, Jacob
1803 Autumn Frost Lane
Baltimore, MD 21209(US)
Inventor: Hamilton, Bruce King
15229 Watergate Road
Silver Spring, MD 20904(US)
Inventor: Tuszyński, George Paul
824 Thoreau Lane
Williamstown, NJ 08094(US)

(43) Date of publication of application:
01.04.92 Bulletin 92/14

(74) Representative: UEXKÜLL & STOLBERG
Patentanwälte
Beselerstrasse 4
W-2000 Hamburg 52(DE)


(84) Designated Contracting States:
DE FR GB IT

(71) Applicant: W.R. Grace & Co.-Conn.
Grace Plaza, 1114 Ave. of the Americas
New York New York 10036(US)
Applicant: THE MEDICAL COLLEGE OF
PENNSYLVANIA
3300 Henry Avenue
Philadelphia, Pa. 19129(US)

(54) Therapeutic use of peptides having thrombospondin-like activity.

(57) Methods for using synthetic analogs of thrombospondin for potentiating or inhibiting thrombospondin-like activity are provided.

FIG. I



EP 0 478 101 A2

This application is a continuation-in-part application of copending U.S. Serial No. 587,197, filed September 24, 1990.

Technical Field

The present invention relates generally to peptide fragments and synthetic analogs of thrombospondin (TSP) which retain thrombospondin-like activity. The peptides retain and mimic the bioactivity of TSP as a potent potentiator or inhibitor of cell adhesion, cell migration, cell attachment, and cell spreading of different cell lines. The peptides also have the ability to inhibit platelet aggregation. In the presence of TSP, the peptides inhibit thrombospondin-like activity and in the absence of TSP, the peptides potentiate thrombospondin-like activity.

The peptides find use in various biological and pharmacological applications. The applications include use as agents in (a) interfering with cancer development by inhibiting metastasis or causing regression of or inhibiting tumor growth; (b) inhibiting platelet aggregation in the therapeutic areas of atherosclerosis and thrombosis; (c) inhibiting angiogenesis; (d) preparing antibodies which are useful as diagnostic or therapeutic reagents; and (e) promoting or inhibiting cellular attachment to surfaces.

Background

Thrombospondin (also known as thrombin sensitive protein or TSP) is a 450,000 molecular weight protein composed of three identical disulfide-linked polypeptide chains (Lawler et al. *J. Cell Biol.* (1986) 101:1059-71). TSP is secreted by platelets in response to physiological activators such as thrombin and collagen (Lawler, *J. Blood* (1986) 67:112-123). TSP comprises 3% of the total platelet protein and 25% of the total platelet alpha granular protein (Tuszynski, G.P. et al. (1985) *J. Biol. Chem.* 260:12240-12245). Other cells also synthesize TSP including fibroblasts (Jaffe, E. A. et al., (1983) *Natl. Acad. Sci. USA* 80:999-1002), smooth muscle cells (Raugei, G. J. et al., (1982) *J. Cell Biol.* 95:351-354), and endothelial cells (McPhearson, J. et al. *J. Biol. Chem.* 256:11330-11336). TSP has been found in certain tumor tissues, such as melanoma cells (Varani, J. et al., (1989) *Clin. Expl. Metastasis* 7:319-329), squamous lung carcinoma (Riser, B. L. et al., (1988) *Exp. Cell Res.* 174:319-329) and breast carcinoma (Pratt, D. A. et al., (1989) *Eur. J. Cancer Clin. Oncol.* 25:343-350). In addition, the following tumor cells in culture have been shown to synthesize TSP: fibrosarcoma, rhabdomyosarcoma, glioblastoma, Wilm's tumor, neuroblastoma, teratocarcinoma, choriocarcinoma, melanoma, and lung carcinoma (Mosher, D. F., (1990) *Annu. Rev. Med.* 41:85-97). A number of recent studies have shown that TSP plays a major role in cell-cell and cell substratum adhesion (Tuszynski, G. P. et al., (1987) *Seminars in Thrombosis Hemostasis* (13):361-368, Mosher, D. F., (1990) *Annu. Rev. Med.* 41:85-97). TSP promotes cell attachment, platelet aggregation, and lung tumor colony formation in a murine model of experimental metastasis (Tuszynski, G. P. et al., (1987) *Science* 236:1570-1573, Tuszyński, G. P. et al., (1988) *Blood* 72:109-115). The role of TSP in adhesion is further supported by the observation that the extracellular matrix of most tissues contains TSP.

TSP is composed of linear polypeptide domains that specifically interact with various macromolecules such as plasma and matrix components. For example, TSP forms a complex with heparin (Yabkowitz, R. et al. (1989) *J. Biol. Chem.* 264:10888-10896), fibrinogen (Tuszynski, G. P. et al. (1985) *J. Biol. Chem.* 260:12240-12245), collagen (Mumby, S. M. et al. (1984) *J. Cell Biol.* 98:10888-10896, and plasminogen (Depoli, P. et al. (1989) *Blood* 73:976-902). The structure of TSP is conserved among various animal species as indicated by the fact that the antibody against the human protein cross-reacts with TSP from mouse, rat, pig, cow, sheep, dog, and turkey (Switalska, H. I. et al., *J. Lab Clin. Med.* 106:690-700).

Thrombospondin has been purified by a number of procedures including exclusion chromatography (Lawler et al., *J. Biol. Chem.* (1978) 253:8609-16), heparin affinity chromatography (Lawler et al., *Thromb. Res.* (1981) 22:267-269), fibrinogen affinity chromatography (Tuszynski et al., *J. Biol. Chem.* (1985) 260:12240-5), barium chloride precipitation (Alexander et al., *Biochem. J.* (1984) 217:67-71) and anion exchange chromatography with HPLC (Clezarolin et al., *J. Chromatog.* (1984) 296:249-56).

The complete amino acid sequence of TSP has been deduced from DNA clones prepared by various groups including Lawler et al., *J. Cell Biol.* (1986) 103:1635-48; Kobayashi et al., *Biochemistry* (1986) 25:8418-25; Dixit et al., *Proc. Natl. Acad. Sci.* (1986) 83:5449-53; and Hennessy et al., *J. Cell Biol.* (1989) 108:729-36.

Cell adhesion is critical to the development and survival of multicellular organisms. The process of cell adhesion is complex requiring numerous extracellular proteins such as fibronectin, vitronectin, collagen, laminin, and TSP and numerous families of cellular receptors such as the integrins and cellular adhesion molecules (CAMS). These molecules are involved in the adhesion of both normal and tumor cells and have

been studied quite intensively in recent years.

The amino acid sequence, Arg-Gly-Asp (RGD), was established as a cell attachment domain in fibronectin (Pierschbacher, M.D. and Ruoslahti, E., (1984) Nature (London) 309:30-32). The same or related sequences have been discovered in many proteins and serve as cell binding sites for such macromolecules as fibrinogen (Ginsberg, M. D. et al., (1985) J. Biol. Chem. 260:11891-11896). However, it appears that the adhesive function of laminin may not be based on the RGD sequence, but on a peptide segment of the B1 chain containing the amino acid sequence tyrosine-isoleucine-glycine-serine-arginine (YIGSR) (Sasaki, M. 1987, Proc. Natl. Acad. Sci 84:935-938). Synthetic peptides containing the RGD and YIGSR sequence promote cell adhesion.

10 The therapeutic use of synthetic peptides based on the adhesive domains of fibronectin and laminin have recently been reported. Humphries et al. (2986) Science 233:467-470) were the first to demonstrate that co-injection of the pentapeptide GRGDS with B16-F10 murine melanoma cells dramatically inhibited the formation of lung colonies in C57BL/6 mice. Another synthetic peptide which was derived from laminin (YIGSR) also dramatically inhibited B16-F10 melanoma cell metastasis in C57B1/6 mice (Kleinman, H. K. et 15 al., (1987) Science 238:1132-1133; Kleinman, H. K. et al., (1990) Proc. Natl. Acad. Sci. USA 87:2279-2283). The inhibitory activity of these peptides may be due to competition with endogenous laminin and fibronectin-dependent adhesion of tumor cells to the vascular bed of the target organ during the metastatic dissemination of the tumor cells.

Because metastasis is a step-by-step process involving the transfer of tumor cells from one site to another through the lymphatic and blood circulation and platelet reduction in animals effectively blocked metastasis in animals (Gasic et al, (1968) Proc. Natl. Acad. Sci USA 48:46-52), platelets have been thought to play a special role in the development of metastasis. Since TSP comprises 25% of the total alpha granular platelet secreted-protein, TSP would be expected to have a major role in the hematogenous transfer of tumor cells to distant organs. Indeed, TSP has been shown to promote tumor cell metastasis in a 25 murine model (Tuszynski et al, (1987) 47:4130-4133). In addition, events which accompany platelet activation, such as: secretion of adhesive proteins, platelet aggregation, activation of proteolytic enzymes, and activation of the clotting cascade have all been shown to play a significant role in tumor cell metastasis (Gasic, G. J., (1984) Cancer Metastasis Rev. 3:99-116).

Adhesive proteins which are part of the extracellular matrix control the movement, growth, and 30 morphology of many cell types. Extracellular matrix proteins interact with tumor cell receptors and affect tumor cell adhesion to basement membrane collagen in different ways. For example, exposure of melanoma cells in vitro to laminin resulted in increased capacity of tumor cells to adhere to the basement membrane and to produce lung tumor colonies (Barsky, S. H. et al., (1984) J. Clin. Inv. 74:843-848; Terranova, V. P. et al., (1984) Science 226:982-985).

35 In view of the information described above, TSP may play an important role in many diverse and clinically important processes, such as: cell migration, wound healing, nerve regeneration, and tumor cell metastasis. To better understand the pathophysiology of these processes at the molecular level, assignment of each of the biological activities of TSP to a specific subdomain or oligopeptide of TSP would provide valuable information. Specifically, detailed knowledge of the structure of domains of the TSP and TSP 40 receptors could be used to design TSP antagonist peptides which could block pathophysiological activities of TSP such as TSP-dependent tumor cell metastasis formation.

TSP contains three homologous peptide sequences designated type I, II, and III repeats (Lawler and Hynes, (1986) J. Cell Biol. 103:1635-1648). The three repeats consist of approximately 60 amino acids each containing six cysteine residues. Type I repeats exhibit homology with peptide segments found in a number 45 of diverse proteins. We have identified two hexapeptide sequences in TSP (CSTSCG and CSVTCG) that are either totally conserved in other proteins or present with one or two conservative amino acid substitutions in apparently unrelated proteins or encoded or predicted by their cdna sequence. The prevalence of the conserved sequences is indicated in Table I below.

TABLE I

<u>Protein</u>	<u>Sequence</u>	<u>Reference</u>
TSP	CSVTG CSTSCG	Lawler et al., (1986), <u>J. Cell Biol.</u> 103:1635-48
Circumsporozoite	CSVTG	Dame J. B. et al., (1984) <u>Science</u> 225:593-599
Trap	CSVTG	Robson K. J. H. et al., (1988) <u>Nature</u> 335:79-82
Properdin	CSVTG	Goundis, D. et al. (1988) <u>Nature</u> 335:82-85
Glycoprotein E Herpes simplex I	CVVTCG	McGoech D. J. et al., (1985) <u>J. Mol. Biol.</u> 181:1-13
Cytochrome C oxidase polypeptide II	CSETCG	Lawson, J. E. et al., (1985) <u>Curr. Genet.</u> 9:351-360
Respiratory nitrate reductase beta chain	CSVTCK	Blasco, F. et al. (1989) <u>Mol. Gen. Genet.</u> 218:249-256
Bird spider 18S ribosomal RNA	CSVSCG	Hendriks L. et al., (1989) <u>Eur. J. Biochem.</u> 177:15-20
Chicken alpha tubulin	CSVVCG	Lemischka I. R. et al. (1981) <u>J. Mol. Biol.</u> 151:101-120
Zebrafish homeobox gene	CSKTCG	Njolstad P. R. et al., (1990) <u>EMBO J.</u> 9:515-524
E. coli gut operon	CSVTGX	Yamada M. et al., (1987) <u>Biol. Chem.</u> 262:5455-5463
E. Coli ATPase	CSVTGM	Kanazawa H. et al., (1981) BBRC:103:613-620
Rat liver apolipoprotein A-I	CSVGCG	Poncin J. E. et al., (1984) <u>Eur. J. Biochem.</u> 140:493
Tryptophan synthetase	CWVTG	Brosius, J. et al., (1982) <u>Gene</u> 17:223-228
Highlands J virus	CSVTCL	Ou J. H. et al., (1982) <u>J. Mol. Biol.</u> 156:719-730

	Human c-myb proto-oncogene	CSVTCRK CRVHCP	Slamon D. J. et al., (1986) <u>Science</u> 233:347-351
5	Antistasin	CRKTCP CRVHCP	Ginsberg V. et al. (1990) <u>J. Biol. Chem.</u> 264:12138-12140
	Etp100	CVCECG CSATCG CSRTCG CSEQCG	Tomley F. et al (1989) <u>5th International Cocciosis Conference</u> 469-573
10	Human desmin	CSVTCCH	Li Z. et al., (1989) <u>Gene</u> 78:243-254
15	Human related mammary tumor virus	CSVPCG	May F. E. B. et al., <u>J. Virol.</u> 60:743-749
	Human proto- oncogene c-fes/fps	CSRTCG	Ouweland A. M. W. et al., <u>EMBO J.</u> 4:2897-2903
20	Platelet GPIIb	CSVTCR	Bray P. F. et al., (1987) <u>J. Clin. Invest.</u> 80:1812-1817

The present invention provides thrombospondin fragments and analogs which mimic or inhibit the biological activity of intact thrombospondin which find use in a variety of biological, prophylactic or therapeutic areas.

Summary of the Invention

30 It has now been found that a class of fragments or synthetic analogs from a specific domain of thrombospondin have a variety of uses. These peptides retain and mimic the bioactivity of TSP as a potent potentiator or inhibitor of cell adhesion, cell migration, cell attachment, and cell spreading. These peptides, by means of their adhesive activity, are capable of potentiating and inhibiting tumor cell growth and metastasis, cell adhesion, angiogenesis and platelet aggregation. The potentiation and inhibition properties 35 of the peptides have been found to depend on the presence or absence of endogenous TSP. In the presence of endogenous TSP, the peptides inhibit thrombospondin-like activity. In the absence of TSP, the peptides promote thrombospondin-like activity.

In one aspect, the peptides are useful in various therapeutic areas including cancer, atherosclerosis, thrombosis, and inflammatory diseases. The peptides interfere with cancer development by inhibiting 40 metastasis or causing regression of or inhibiting tumor growth. The ability of the peptides to inhibit platelet aggregation make them useful in atherosclerosis and thrombosis prevention or treatment. The peptides inhibit angiogenesis making them useful for treating or preventing inflammatory disorders.

In another aspect, the peptides and antibodies against the peptides are useful as therapeutic and diagnostic reagents. The therapeutic uses of the antibodies are similar to those described above.

45 Another objective of the invention is to provide medical devices which employ the peptides or antibodies of this invention. The use of the peptides or antibodies can inhibit thrombospondin-like activity (i.e., inhibit platelet aggregation) to facilitate the passage of samples containing endogenous TSP and reduce fouling of the device.

In another aspect, it is also possible to take advantage of the ability of the peptides and antibodies to 50 potentiate thrombospondin-like activity under certain circumstances. The peptides and antibodies can be used for preparing surfaces for optimal cell culture, derivatization of various prosthetic materials, and to promote binding of surrounding tissues. Medical devices can also be designed which make use of such substrates to attract cells to a surface in vivo or even to promote the growing of a desired cell type on a particular surface prior to grafting.

55 The TSP peptides and analogs of this invention have been shown to have thrombospondin-like activity. The present invention is, therefore, in one aspect directed to polypeptide compounds having thrombospondin-like activity which are identified by the formula:

R₁-X₁-X₂-X₃-X₄-X₅-R₂

wherein:

- 5 R₁ is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues, preferably up to 20 amino acid residues and most preferably up to 10 amino acid residues or the desamino form thereof;
- X₁ and X₅ are the same or different neutral/small amino acid residues, preferably selected from the group consisting of cysteine, serine, and alanine, and most preferably cysteine or alanine.
- 10 X₂, X₃, and X₄ are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues, preferably selected from the group consisting of valine, threonine, serine, and arginine;
- R₂ is a protected or unprotected terminal carboxyl group including hydroxyl, carboxyl, or up to one hundred amino acid residues, preferably up to 20 amino acid residues and most preferably up to 10 amino acid residues, including carboxamide or alkylamide forms thereof, preferably selected from the group consisting of lysine, glycine, and arginine;

the structure of the polypeptide is optionally cyclized through a bond between the X₁ and X₅, preferably a disulfide bond, or a bond between R₁ and R₂.

20 Also provided in accordance with aspects of the invention are pharmaceutical compositions which contain the above-recited polypeptide compounds together with a pharmaceutically acceptable liquid, gel or solid carrier. Administration of therapeutically effective doses of these compositions can provide effective enhancement or inhibition of thrombospondin-like activity to animals, particularly vertebrates such as mammalian and avian hosts.

25

Brief Description of the Drawings

- Figure 1 shows the results of HPLC analysis on peptide CSVTCG-NH₂.
- Figure 2 shows the results of HPLC analysis on peptide CSVTCG.
- 30 Figure 3 shows the results of HPLC analysis on peptide CSVTCG which is cyclized via a disulfide bond.
- Figure 4 shows the ability of the peptides of the invention to inhibit adhesion of melanoma cells.
- Figure 5 shows the ability of the peptides of the invention to act in collagen dependent melanoma cell adhesion.
- 35 Figure 6 demonstrates that *in vivo* the peptides of the invention have antimetastatic activity.
- Figure 7 compares the lungs of mice treated with and without the peptides of the invention in the presence of melanoma cells.
- Figure 8 shows the ability of the peptides of the invention to inhibit ADP-induced platelet aggregation.
- 40 Figure 9 shows the ability of the peptides of the invention to inhibit collagen-induced platelet aggregation.
- Figure 10 shows a dose response of the ability of peptide CSVTCG to inhibit collagen-induced platelet aggregation.
- Figure 11 shows the ability of the peptides of the invention to support the adhesion of human platelets.
- 45 Figure 12 shows the ability of an antibody against a peptide of the invention to inhibit ADP-induced platelet aggregation.
- Figure 13 shows that *in vivo* an antibody against a peptide of the invention has antimetastatic activity.

50

Detailed Description of the Invention

In accordance with the present invention, a class of fragments and analogs of thrombospondin is provided which is capable of inhibiting or mimicing the activity of thrombospondin in mammals *in vivo*.

55

A. Definitions

"Thrombospondin-like activity" is defined herein as any activity that mimics the known biological

activities of thrombospondin. These activities include cell-adhesion promoting activity, cell mitogenic activity, cell chemotactic activities, and hemostatic activities and any activities that derive from these activities such as tumor cell, microbial, or parasite metastasis activity, platelet aggregating activity, fibrinolytic activity and immune modulation.

5 "Cell adhesion activity" is defined herein as the ability to promote or inhibit the attachment of cells, preferably mammalian cells, to a substrate.

"Platelet aggregation activity" is defined herein as the ability to inhibit the capacity of platelets to aggregate.

10 "Antimetastatic activity" is defined herein as the ability to prevent or greatly reduce the extent or size of tumor cell metastasis, or inhibit or cause regression of primary solid tumors.

"Atherosclerosis activity" is defined herein as the capacity of thrombospondin to inhibit atherosclerotic lesion formation. The atherosclerotic lesion is defined as the degenerative accumulation of lipid-containing materials, especially in arterial walls.

15 "Anti-thrombotic activity" is defined herein as the ability to either inhibit the aggregation of platelets or to antagonize the formation of a thrombus.

"Thrombolytic activity" is defined herein as the ability to disrupt the structure of a thrombus.

"Angiogenesis activity" is defined herein as the ability to inhibit the formation of blood vessels or lymph vessels.

The sequence of amino acid residues of the present polypeptide compounds, the core pentapeptide, 20 and preferred embodiments thereof, are defined in terms of amino acids of certain characteristics of particular subclasses.

Amino acid residues can be generally subclassified into four major subclasses as follows:

25 Acidic, i.e., the residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.

Basic, i.e., the residue has a positive charge due to association with H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.

30 Neutral/non-polar, i.e., the residues are not charged at physiological pH and the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.

Neutral/polar, i.e., the residues are not charged at physiological pH and the residue is attracted by aqueous solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.

35 It is understood, of course, that in a statistical collection of individual residue molecules some molecules will be charged, and some not. To fit the definition of charged, a significant percentage (at least approximately 25%) of the individual molecules are charged at physiological pH.

40 Amino acid residues can be further subclassified as cyclic or non-cyclic, a self-explanatory classification with respect to the side chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of three carbon atoms or less. Small residues are, of course, always non-cyclic.

For the naturally occurring protein amino acids, subclassification according to the foregoing scheme is as follows:

Acidic: Aspartic acid and Glutamic acid;

45 Basic/non-cyclic: Arginine and Lysine;

Basic/cyclic: Histidine;

Neutral/polar/small: Glycine, Serine and Cysteine;

Neutral/polar/large/non-cyclic: Threonine, Asparagine and Glutamine;

Neutral/polar/large/cyclic: Tyrosine;

50 Neutral/non-polar/small: Alanine;

Neutral/non-polar/large/non-cyclic: Valine, Isoleucine, Leucine and Methionine;

Neutral/non-polar/large/cyclic: Phenylalanine and Tryptophan.

The protein amino acid proline, although within the classification neutral/non-polar/large/cyclic, is not included as an alternative due to its known effects on the secondary conformation of peptide chains.

55 Certain commonly encountered non-natural amino acids, such as desamino Tyrosine (des Tyr), agmatine (Agm), n-formyl tryptophan (f-Trp), alpha-aminoisobutyric acid (Aib), and sarcosine (Sar), statine, ornithine (Orn), homolysine, homoserine, homoarginine, norleucine (Nle), norvaline may also be incorporated into the compounds of the invention. Desamino tyrosine is incorporated at the N-terminus. Agmatine and

EP 0 478 101 A2

statine are incorporated at the C-terminus. Based on the above definition, n-formyl Trp is neutral/non-polar/large/cyclic, Sar is neutral/non-polar/small, Aib is neutral/non-polar/non-cyclic, Orn is basic/non-cyclic, homolysine is basic/non-cyclic, homoserine is neutral/polar/small, homoarginine is basic/non-cyclic, norleucine is neutral/non-polar/large/non-cyclic, and norvaline is neutral/non-polar/large/non-cyclic.

5 The nomenclature used to describe polypeptide compounds of the present invention follows the conventional practice wherein the amino group is presented to the left and the carboxy group to the right of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxy-terminal groups, although not specifically shown, will be understood to be in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid 10 structure formulae, each residue is generally represented by a one-letter or three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following schedule:

	Amino Acid	Three-letter Symbol	One-letter Symbol
15	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic acid	Asp	D
20	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glycine	Gly	G
	Histidine	His	H
25	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
	Phenylalanine	Phe	F
30	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
35	Valine	Val	V

In the present application, the L-form of any amino acid residue having an optical isomer is intended unless otherwise expressly indicated, e.g., by the symbol "[D-X_n]."

40 Compounds within the scope of the present invention can be obtained by modifying the disclosed formulae in numerous ways, while preserving the activity of the polypeptide compounds thus obtained. For example, while the amino acids of these compounds are normally in the natural L optical isomer form, one or more, usually two or less and preferably one amino acid may be replaced with the optical isomer D form, or a D,L-racemic mixture can be provided in the molecules comprising the polypeptide compound.

45 Additionally, a disulfide linkage may be present or absent in the compounds of the invention, as long as activity is maintained. As one skilled in the art would recognize, branched or cyclical chains may be produced by the formation of a peptide bond with amino acid side groups that contain amino or carboxyl moieties. Amino acids containing such side groups include, for example, glutamic acid (carboxyl group), aspartic acid (carboxyl group) and lysine (amide group). Branched or cyclical chains may also be produced through the formation of a covalent disulfide bond between amino acid residues having sulfur-containing side groups, such as cysteine.

50 As used herein, "protected" terminal amino group, refers to a terminal amino group coupled with any of various amino-terminal protecting groups traditionally employed in peptide synthesis. Examples of suitable groups include acyl protecting groups, for example, formyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl; aromatic urethane protecting groups, for example, benzyloxycarbonyl; and aliphatic urethane protecting groups, for example, tert-butoxycarbonyl or adamantlyloxycarbonyl. Gross and Mienhofer, eds., The peptides, vol. 3, pp. 3-88 (Academic Press, New York, 1981), disclose numerous suitable terminal amino protecting groups.

55 As used herein, "protected" terminal carboxyl group, refers to a terminal carboxyl group coupled with

any of various carboxy-terminal protecting groups. As will be readily apparent to one skilled in the art, suitable groups include tert-butyl, benzyl or other acceptable groups linked to the terminal carboxyl group through an ester or ether bond.

5 Amino acid residues contained within the compounds, and particularly at the carboxy- or amino- terminus, can also be modified by methylation, amidation, acetylation or substitution with other chemical groups which can, for example, change the circulating half-life, resistance to proteases and solubility of the compounds without adversely effecting their activity.

In addition to the preceding definitions, the following abbreviations have been used throughout in describing the invention:

10	BCA	bicinchoninic acid
	BSA	bovine serum albumin
	t-Boc	t-butyloxycarbonyl
	Bzl	benzyl
	°C	degrees centigrade
15	DCM	dichloromethane
	DIEA	diisopropyl ethyl amine
	DMEM	Dulbecco's minimum essential medium
	DMF	dimethyl formamide
	HF	hydrogen fluoride
20	HOBT	1-hydroxybenzotriazole
	HPLC	high performance liquid chromatography
	mBHA	methylbenzhydrylamine
	μg	microgram
	μl	microliter
25	ml	milliliter
	mM	millimolar
	nm	nanometers
	NMP	N-methylpyrrolidone
	%	percent
30	PAM	phenylacetamidomethyl
	PBS	phosphate buffered saline
	TFA	trifluoroacetic acid

B. Preferred Embodiments

35

The polypeptide compounds of the invention all contain the core pentapeptide sequence:

R₁-X₁-X₂-X₃-X₄-X₅-R₂

40 wherein:

R₁ is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues, preferably up to 20 amino acid residues and most preferably up to 10 amino acid residues, or the desamino form thereof;

45 X₁ and X₅ are the same or different neutral/small amino acid residues, preferably selected from the group consisting of cysteine, serine, and alanine, and most preferably cysteine or alanine.

X₂, X₃, and X₄ are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues, preferably selected from the group consisting of valine, threonine, serine, and arginine;

50 R₂ is a protected or unprotected terminal carboxyl group including hydroxyl, carboxyl, or up to one hundred amino acid residues, preferably up to 20 amino acid residues and most preferably up to 10 amino acid residues, including carboxamide or alkylamide forms thereof, preferably selected from the group consisting of lysine, glycine, and arginine;

55 the structure of the polypeptide is optionally cyclized through a bond between the X₁ and X₅, preferably a disulfide bond, or a bond between R₁ and R₂.

Particularly preferred are those embodiments wherein the sequence is selected from the group consisting of the following wherein the sequence includes C-terminal acid and amide forms, disulfide linked

EP 0 478 101 A2

forms and blocked cysteine forms:

5 CSVTCG (SEQ ID NO:1)
CSVTCR (SEQ ID NO:2)
CSTSCR (SEQ ID NO:3)
CSTSCG (SEQ ID NO:4)
10 CRVTCG (SEQ ID NO:5)
RCRVTCG (SEQ ID NO:6)
ASVTAR (SEQ ID NO:7)
15 CSVTCK (SEQ ID NO:8)
CSTSCK (SEQ ID NO:9)
CSRTCG (SEQ ID NO:10)
CRTSCG (SEQ ID NO:11)
20 CRVTC (SEQ ID NO:12)
CSTSC (SEQ ID NO:13)
PCSVTCR (SEQ ID NO:14)

25
The most preferred embodiments are selected from the group consisting of:

30

35

40

45

50

55

	<u>SEQ ID NO:</u>	<u>SEQUENCE</u>
	1	CSVTCG
5	1	CSVTCG-NH ₂
	1	CSVTCG
10	1	CSVTCG (blocked cysteines)
	2	CSVTCR
10	2	CSVTCR-NH ₂
	2	CSVTCR
15	3	CSTSCR
	3	CSTSCR-NH ₂
	4	CSTSCG
	4	CSTSCG-NH ₂
20	4	CSTSCG
	4	CSTSCG (blocked cysteines)
	5	CRVTCG
25	5	CRVTCG-NH ₂
	5	CRVTC
	5	CRVTCG-NH ₂
30	6	RCRVTCG
	7	ASVTAR
	8	CSVTCK
	9	CSTSCK-NH ₂
35	10	CSRTCG
	10	CSRTCG-NH ₂
	11	CRTSCG-NH ₂
40	12	CRVTC -NH ₂
	13	CSTSC
	14	PCSVTCR-NH ₂
45	14	PCSVTCR-NH ₂

Compounds within the scope of the present invention can be synthesized chemically by means well known in the art such as, e.g., solid phase peptide synthesis. The synthesis is commenced from the carboxy-terminal end of the peptide using an alpha-amino protected amino acid. t-Butyloxycarbonyl (Boc) protective groups can be used for all amino groups even though other protective groups are suitable. See Stewart et al., "Solid-Phase Peptide Synthesis," W. H. Freeman Co., San Francisco (1969) and Merrifield, J. Am. Chem. Soc. 85: 2149-2154 (1963), Vale et al., Science 213, 1394-1397 (1981), and Marke et al., J. Am. Chem. Sci. 103, 3178 (1981). Other preparative methods which may be employed include the process of Houghton Proc. Natl. Acad. Sci. 82:5132 (1981), or another preferable synthesis procedure particularly for small branched or cyclic chain peptides which would include conventional liquid phase processes. The liquid phase process, as well as other synthesis methods are described in "Principle of Peptide Synthesis" M. Bodansky Ed. (Spring-Verlag 1984. These and other methods of peptide synthesis are also exemplified by U.S. Patents Nos. 3,862,925, 3,842,067, 3,972,859 and 4,105,602, 4,683,291, 4,244,946, and 4,305,872.

Conveniently, compounds may be synthesized using manual techniques or automatically employing, for example, an Applied BioSystems 430A Peptide Synthesizer (Foster City, California) or a Biosearch SAM II automatic peptide synthesizer (Biosearch, Inc., San Rafael, California), following the instructions provided in the instruction manual supplied by the manufacturer.

- 5 Although a purity of greater than 95 percent for the synthesized peptide is preferred, lower purity may be acceptable. To obtain cyclic peptides, where for example the two cysteine amino acids are bonded or where the residues contain a disulfide bridge which may be formed by oxidizing of a dilute aqueous solution of the peptide with $K_2[Fe(CN)_6]$. Other means of cyclizing which are known in the art may also be utilized. The stabilized cyclized peptide of the present invention can also be prepared by forming a peptide bond
10 between non-adjacent amino acid residue. A procedure for forming such peptide bond is provided in Schiller et al., Int. J. Peptide Protein Res. (1985) 25:171.

It will be readily appreciated by those having ordinary skill in the art of peptide synthesis that the intermediates which are constructed in accordance with the present disclosure during the course of synthesizing the present compounds are themselves useful compounds and are thus within the scope of the
15 invention.

Alternatively, selected compounds of the present invention can be produced by expression of recombinant DNA constructs prepared in accordance with well-known methods. Such production can be desirable to provide large quantities or alternative embodiments of such compounds.

20 **C. Administration**

Compounds of the present invention have thrombospondin-like activity in the intact animal. Compounds of the present invention and compositions containing them which are shown to have the physiological effect of inhibiting or mimicing the effect of intact thrombospondin find use in numerous therapeutic and
25 prophylactic applications, such as cancer therapy, wound healing, thrombotic or thrombolytic conditions, angiogenesis, or cell attachment.

Thus the present invention also provides compositions containing an effective amount of compounds of the present invention, including the nontoxic addition salts, amides and esters thereof, which may, alone, serve to provide the above-recited therapeutic benefits. Such compositions can also be provided together
30 with physiologically tolerable liquid, gel or solid diluents, adjuvants and excipients.

These compounds and compositions can be administered to animals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will range from about 1 μ g to 300 mg/kg, more usually 10 μ g to 30 mg/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant
35 infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits have been obtained.

Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active ingredient is often mixed with diluents or excipients which
40 are physiologically tolerable and compatible with the active ingredient. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired, the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents, and the like.

The compositions are conventionally administered parenterally, by injection, for example, either subcutaneously or intravenously. Additional formulations which are suitable for other modes of administration include suppositories, intranasal aerosols, and, in some cases, oral formulations. For suppositories, traditional binders and excipients may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and contain 10%-95% of active ingredient, preferably 25%-70%. These oral formulations include formulations designed to protect the peptide until it can be absorbed.

55 The peptide compounds may be formulated into the compositions as neutral or salt forms. Pharmaceutically acceptable non-toxic salts include the acid addition salts (formed with the free amino groups) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups

may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

In addition to the compounds of the present invention which display thrombospondin-like activity, 5 compounds of the present invention can also be employed as intermediates in the synthesis of such useful compounds.

The compounds of the invention can be homopolymerized to themselves (i.e., (peptide)n) or, heteropolymerized to one another (i.e., (peptide 1-peptide 2). The compounds can also be cyclized through disulfide or other means. The compounds can also be conjugated to biocompatible polymeric compounds, 10 such as BIOPOL™ polymers (W. R. Grace & Co.-Conn.).

While not wishing to be bound by any theory, it is believed that the compositions of the invention act as agonists or antagonists to native thrombospondin. These compounds are also believed to act as agonists or antagonists to circumsporozoite protein, thrombospondin related anonymous protein, antistasin, and properdin complement protein. Further, since the compounds of the invention are small in size (relative to intact 15 thrombospondin) the properties which they exhibit are more likely to be specific in nature, as opposed to the actions of other generally adhesive compounds such as RGD containing compounds (the sequence of which is found in over a hundred proteins) and fibronectin. The side effects of the peptide compounds of the invention are greatly reduced when compared with these broadly adhesive compounds.

20 D. Use

As stated previously, the compounds of the invention can be used in a variety of biological, prophylactic or therapeutic areas. It is contemplated that these compounds are useful in prevention or treatment of any disease state or conditions wherein thrombospondin-like activity plays a role. These disease states and 25 conditions include, but are not limited to, cancer, atherosclerosis, cardiovascular diseases, and inflammatory diseases. Antibodies directed against the compounds of the invention are also useful as diagnostic reagents, therapeutics, or carriers of other compounds. The compounds can also be used in biomedical devices.

Numerous in vitro and in vivo assays can be used to demonstrate compounds having thrombospondin-like activity. These assays include, but are not limited to, cell adhesion assays, platelet aggregation assays 30 and cell proliferation assays.

METASTASIS

35 Metastasis is the spread of disease from one part of the body to another unrelated to it, as in the transfer of the cells of a malignant tumor by way of the bloodstream or lymphatics. It is believed that metastasis is effected through a cascade mechanism which includes adhesion of tumor cells to endothelium, retraction of the endothelium, matrix degradation of the basement membrane and invasion of the tumor cells into the bloodstream. It is further speculated that the platelets play a major role in spreading the 40 tumor cells in the bloodstream and effecting metastatic growth at sites distant from the primary tumor. Intervention at any phase in this cascade could be beneficial to the treatment or prevention of metastatic cancers.

The native thrombospondin molecule has been shown to potentiate tumor cell metastasis (Tuszynski et al., Cancer Research (1987) 47:4130-4133). The mechanisms by which the thrombospondin potentiation 45 occurs are not presently well understood.

Antimetastasis activity is characterized by the ability of the compounds to bind to melanoma cells in vitro (Tuszynski et al., Anal. Bio. (1990) 184:189-91), and the ability to reduce the size and number of tumor colonies in vivo (Tuszynski et al. Cancer Research (1987) 47:4130-4133).

The compounds of this invention are useful as antimetastatic agents, particularly useful as anti-pulmonary metastatic agents. These compounds inhibit the adhesion of metastatic tumor cells, particularly those which are responsive to thrombospondin. The compounds also reduce tumor colony number as well as tumor colony size.

There are a number of mechanisms by which such antimetastatic activity can be occurring. The peptides can be cytotoxic, or inhibit cell proliferation. As inhibitors of cell proliferation, the compounds can 55 act to (1) inhibit mitogenesis, (2) inhibit angiogenesis, or (3) activate the complement pathway and the associated killer cells. It is also possible that, when the peptide inhibits platelet aggregation, it inhibits the ability of the platelets to interact with tumor cells and thus prevents the formation of platelet-tumor emboli which can seed distant organs.

The compounds of the invention can also find use in biomedical devices. Since the compounds have the ability to promote the attachment of metastatic tumor cells, it is possible to coat a biomedical device with the compounds to effect the removal of circulating tumor cells from blood or lymph. The biomedical device is also useful to trap hepatomas.

5 Another use of the compounds is as a carrier to target toxins, drugs, hormones or imaging agents to metastatic tumor cells for diagnostic or therapeutic purposes. These carriers would also bind to hepatomas.

ANTI-PLATELET AGGREGATION

10 Platelet aggregation is a normal and beneficial process to stop bleeding of damaged tissue. However, platelet aggregation can cause problems following cardiovascular treatment such as angioplasty, thrombolytic therapy or vascular grafting. Platelets contain as much as 25% of the TSP protein in the total alpha granular platelet secreted-protein. Therefore, introduction of a peptide containing the pentapeptide sequence which is conserved in the TSP molecule and which binds to receptors on the surface of a platelet can prevent the platelet from aggregating and forming a clot.

15 Anti-platelet aggregation activity is characterized by a number of assays, including (1) inhibition of ADP or thrombin-induced platelet aggregation in washed platelets; (2) inhibition of ADP-induced platelet aggregation in platelet-rich plasma; and (3) inhibition of collagen induced platelet aggregation measured *in vivo*.

20 The peptides can be useful in numerous therapeutic applications, such as during surgery on peripheral arteries, in cardiovascular surgery or after angioplasty. The peptide can also be used prophylactically to treat and prevent cardiovascular and ischemic disorders and diseases which are associated with platelet aggregation. A drug based on the peptides of the invention can be used as an adjunct to angioplasty and thrombolytic therapy for use with other clot-dissolving agents which are currently in the market (e.g., tPA, streptokinase). Such an agent does not aggravate bleeding or have the risk of side effects common to 25 synthetic anti-platelet drugs. Additionally, such a peptide can help to keep open small diameter vascular grafts (such as those used in heart bypass surgery). Similar applications are envisioned for patients at risk for stroke. It is believed that the peptides have a short duration of activity in the blood circulation which make the peptides desirable for use in therapeutic treatments where inhibition of platelet aggregation for short duration of time (e.g., bypass surgery, angioplasty, etc.) is useful.

30 The peptides can also be useful in dialysis applications. The peptide could be administered to the dialysis patient in an effort to eliminate platelet aggregation on the dialysis membrane. Alternatively, the dialysis membrane could be coated with the peptide to prevent platelet aggregation as the fluid samples pass through the medical device.

ANGIOGENESIS

35 Angiogenesis is the formation of blood and lymph vessels. The compounds of this invention are useful for inhibiting angiogenesis. Angiogenesis is essential during development, in wound healing and for the growth of solid tumor. Angiogenesis is a complex process, requiring the sprouting and migration of 40 endothelial cells, their proliferation and their differentiation into a tube like structure and the production of a basement membrane matrix around the vessel (Herbert et al. 1988, *L. Cell. Biol.* 106, 1365-1373). Angiogenesis is also essential to tumor development and growth and metastasis. Prevention of angiogenesis can inhibit solid tumor growth. Use of the compounds of this invention can inhibit one or more steps in the cascade process of angiogenesis and therefore such peptide may be useful clinically to inhibit 45 metastasis. The compounds of this invention are useful in the modulation of angiogenesis, particularly in inhibiting or preventing tumor growth. The compounds of the invention are also useful in inhibiting or preventing inflammatory diseases including diabetic retinopathy, neovascular glaucoma and rheumatoid arthritis.

50 Standard angiogenesis assays are well known in the art. These assays include, but are not limited to, proliferation and migration studies using various cell lines, collagenase inhibition and *in vivo* neovascularization on chicken chorioallantoic membranes (CAM assay).

ANTIBODIES

55 Antibodies, both monoclonal and polyclonal, directed to peptide compounds of the present invention are useful in various therapeutic and diagnostic areas. The present invention also pertains to such antibodies. Antibodies directed against the peptides of the invention can be useful in any other of the above-described therapeutic or diagnostic uses or in the above-described biomedical devices.

To prepare antibodies, any one of a number of techniques which are known in the art can be employed. In one such technique, polyclonal antibodies may be synthesized by injecting an animal (for example, a rabbit) with one or more compounds of the invention. After injection, the animal naturally produces antibodies to these compounds. When the antibody level rises to a sufficient level, antibody-containing

- 5 blood, called antiserum, is then drawn from the animal, and the compound-specific antibody is isolated from other antibodies in the antiserum by any one of a number of separation techniques (for example, affinity chromatography). Monoclonal antibodies may be prepared using the technique of Kohler and Milstein, *Nature* 256, pp. 495-497 (1975).

Compounds of the present invention can also be used for preparing antisera for use in immunoassays 10 employing labelled reagents, usually antibodies. Conveniently, the polypeptides can be conjugated to an antigen by means of dialdehydes, particularly from 4 to 6 carbon atoms and aliphatic, or carbodimide. These compounds and immunologic reagents may be labelled with a variety of labels such as chromophores, fluorophores such as, e.g., fluorescein or rhodamine, radioisotopes such as ^{125}I , ^{35}S , ^{14}C , or ^3H , or magnetized particles, by means well known in the art.

- 15 These labelled compounds and reagents, or labelled reagents capable of recognizing and specifically binding to them, can find use as, e.g., diagnostic reagents. Samples derived from biological specimens can be assayed for the presence or amount of substances having a common antigenic determinant with compounds of the present invention.

Thrombospondin levels are elevated in the serum of patients with metastatic breast and colon cancer 20 (Tuszynski et al., *Thrombosis Haemostas* (1989) 62:418 and Smith et al., *Proceedings American Association of Clinical Oncology* (1990) 9:6). Antibodies against the peptides of the invention can be useful as reagents in diagnostic/prognostic assays for various types of cancer, including but not limited to, gastrointestinal tract (gastric, colonic, and rectal) carcinomas, breast carcinomas and hepatic carcinomas.

- 25 The polyclonal and monoclonal antibodies can find therapeutic use in any of the above-described uses, particularly cancer therapies. First, the antibodies can be used to sequester thrombospondin. This is useful since thrombospondin mediates tumor cell metastasis. Second, the antibodies can be used to block thrombospondin present on the tumor cell surface. Third, cytotoxic drugs, hormones, or imaging agents can be coupled to the antibodies for use in cancer therapy. Fourth, a biomedical device can be coated with the 30 antibodies to remove excess thrombospondin from serum or the remove cells which bear thrombospondin on the cell surface.

ADHESION AND CELL ATTACHMENT

The peptides of the present invention can be used for preparing a surface for optimal cell culture, and 35 for prosthetic materials to promote bonding with surrounding tissue. These peptides can be useful as a cell attachment protein to provide a substrate to which cells will attach by treating a hydrophobic surface such as untreated synthetic plastic resin and especially materials which are used for different membrane applications, e. g., nitrocellulose or polysulfone or comparable material with the peptide. The cell attachment properties of the peptides can also be used to couple polypeptides covalently to a solid support such as 40 gels or synthetic resins or long chain polysaccharide. This latter approach can be used for different affinity chromatography applications. Another important application of using such peptides are the use of the peptide in commercial cell attachment surfaces, wherein the particles are coated with gelatin, making it possible to grow the same adherent cells in a much smaller volume of media than would be possible in dishes. Medical devices can be designed for use with such peptides to attach cells to the surface *in vivo*, or 45 even to promote the growth of a desired cell type on particular surfaces prior to grafting. An example of this is attachment of islet cells to a membrane or growth of endothelial cells on a prosthetic blood vessel or vascular graft. Such peptides can find uses in coating a patch graft or the like for aiding in wound healing.

- The peptides of the invention can also be used to isolate thrombospondin cell surface receptors from extracts of cells or cell membranes. Standard procedures such as affinity chromatography can be 50 employed. The thrombospondin cell surface receptors can be used to develop better thrombospondin analogs or to remove excess thrombospondin from serum.

The following examples are provided by way of illustration, rather than implying any limitation of the subject matter.

EXAMPLES

The peptides of this invention can be synthesized by conventional methods of peptide synthesis. The preferred conventional methods use the procedures described in *Int. J. Pept. Proc. Res.* 21, 57-63 (1983).

EP 0 478 101 A2

Also preferred is the solid phase synthesis of Merrifield, J. Amer. Chem. Soc. 85, 2149-2154 (1963); Science 150, 178-185 (1965); Ibid. 232, 341-347 (1986). Solid phase synthesis is generally initiated from the C-terminal of the peptide by coupling a protected alpha amino acid to a suitable resin, e.g., phenylacetamidomethyl (PAM) polystyrene resin, or p-methylbenzhydrylamine (mBHA) resin when synthesizing a peptide with a C-terminal carboxamide. During synthesis, suitable amino acid side-chain protecting groups are used as needed. Thus, aspartic acid is protected on the beta-carboxyl group as the benzyl ester and arginine is protected on the guanidino group by tosyl. After the desired peptide has been synthesized, the peptide is cleaved from the resin and protecting groups are removed by treatment with a reagent such as hydrogen fluoride (HF). The peptide can then be purified by high performance liquid chromatography (HPLC) or other such methods of peptide purification. Background information on the established procedures for solid phase peptide synthesis can be found in "Solid Phase Peptide Synthesis" by Stewart and Young, W. H. Freeman & Co., San Francisco, 1969.

In accordance with the above description, the following procedures were used for the chemical synthesis of novel synthetic peptides:

15

Example 1

Synthesis of the Peptide Sequence CSVTCG (SEQ ID NO:1) with C Terminal Amide

20 An appropriate resin 4-methylbenzhydrylamine (MBHA) for C-terminal amide was sealed into polypropylene mesh packets (64 μ). All packets were placed into a common vessel with CH₂Cl₂ and vigorously shaken to wash and swell the resin. All subsequent steps involved vigorous shaking to ensure adequate solvent transfer. The N- α -butoxycarbonyl was then removed by acidolysis using 55% trifluoroacetic acid (TFA)/CH₂Cl₂ for 30 minutes leaving the α -amino acid group in the TFA salt form. The packets were then washed with CH₂Cl₂ (2x), IPA (2x), and CH₂Cl₂ (2x) to remove excess TFA and prepare for neutralization. The IFA salt was neutralized by washing the packets three times with 5% diisopropylethylamine in CH₂Cl₂ for 2 minutes each. This was followed by two washes with CH₂Cl₂ to remove excess base. Packets were then removed from the common vessel and added to their respective 0.2 M amino acid solutions which were prepared from computer generated information prior to neutralization. An equal volume of 0.2 M dipropylcarbodiimide was then added to activate the coupling reaction. After coupling at room temperature for 1 hour, the packets were washed with dimethyl-formamide and CH₂Cl₂ and returned to the common vessel. This process was repeated for each amino acid. Cleavage occurred by reacting the peptide with 92.5% hydrogen fluoride/7.5% anisole at -10 °C to 0 °C over 90 minutes. Anisole was used as a scavenger to react with carbocations produced as a result of the side chain protecting group removal. This solution was then removed using a strong flow of N₂ followed by the use of aspirator vacuum, while maintaining the temperature at 0 °C. Residual anisole was removed with 2 ethyl ether washes. The peptide was then extracted using 10% acetic acid.

The purity of the crude peptide was checked by analytical RP-HPLC using a Beckman System Gold with a Vydac C-18 column at a flow rate of 1ml/min. The solvent system used was 0.05% aqueous TFA(A) and 0.05% TFA in acetonitrile (B) with a gradient of 5-65% B in 30 minutes measuring the absorbance at 215 μ m. Purification was performed on Waters delta prep. 3,000 preparative HPLC with a Waters prep. Pak Nodule Radial Compression C18 column (25 cm x 5 cm, 10-20 μ). The solvent system was 0.05% aqueous TFA (A) and 0.05% TFA in acetone (B). Various linear gradients were used measuring the absorbance at 230 nm and collecting 40 ml fraction. The fractions were then analyzed on the Beckman analytical system. The desired fractions were pooled and lyophilized. The final dry product was analyzed one more time using analytical RP-HPLC. Typical HPLC chromatograms for this peptide after purification are shown in Figure 1.

Example 2

Chemical Synthesis of the Peptide Sequence CSVTCG Acid (SEQ ID NO:1)

An appropriate resin phenylacetamidomethyl (PAM) for C-terminal acid was sealed into polypropylene mesh packets (64 μ). All packets were placed into a common vessel with CH₂Cl₂ and vigorously shaken to wash and swell the resin. All subsequent steps involved vigorous shaking to ensure adequate solvent transfer. The N- α -butoxycarbonyl is then removed by acidolysis using 55% trifluoroacetic acid (TFA)-/CH₂Cl₂ for 30 minutes leaving the α -amino acid group in the TFA salt form. The packets were then washed with CH₂Cl₂ (2x), IPA (2x), and CH₂Cl₂ (2x) to remove excess TFA and prepare for neutralization. The TFA salt was neutralized by washing the packets three times with 5% diisopropylethylamine in CH₂Cl₂.

EP 0 478 101 A2

for 2 minutes each. This was followed by two washes with CH₂C₁₂ to remove excess base. Packets were then removed from the common vessel and added to their respective 0.2 M amino acid solutions which were prepared from computer generated information prior to neutralization. An equal volume of 0.2 M diisopropylcarbodiimide was then added to activate the coupling reaction. After coupling at room temperature for 1 hour, the packets were washed with dimethylformamide and CH₂C₁₂ and returned to the common vessel. This process was repeated for each amino acid. Cleavage occurred by reacting the peptide with 91.5% hydrogen fluoride/7.5% anisole at -10°C to 0°C over 90 minutes. Anisole was used as a scavenger to react with carbocations produced as a result of the side chain protecting group removal. This solution was then removed using a strong flow of N₂ followed by the use of an aspirator vacuum, while maintaining the temperature at 0°C. Residual anisole is removed with two ethyl ether washes. The peptide is then extracted using 10% acetic acid.

The purity of the crude peptide was checked by analytical RP-HPLC using a Beckman System Gold with a Vydac C-18 column at a flow rate of 1 ml/min. The solvent system used was 0.05% aqueous TFA(A) and 0.05% TFA in acetonitrile (B) with a gradient of 5-65% B in 30 minutes measuring the absorbance at 215 nm. Purification was performed on Waters delta prep. 3,000 preparative HPLC with a Waters prep. Pak Nodule Radial Compression C18 column (25 cm x 5 cm, 10-20 μm). The solvent system was 0.05% aqueous TFA (A) and 0.05% TFA in acetonitrile (B). Various linear gradients were used measuring the absorbance of 230 nm and collecting 40 ml fraction. The fractions were then analyzed on the Beckman analytical system. The desired fractions were pooled and lyophilized. The final dry product was analyzed one more time using analytical RP-HPLC. Typical HPLC chromatogram for this peptide after purification are shown in Figure 2.

Example 3

25 Synthesis of cyclic CSVTCG-Acid (SEQ ID NO:1)

Cyclization of CSVTCG (SEQ ID NO:1) peptide was accomplished by dissolving the crude peptide of Example 2 (52 mg) in 500 ml deoxygenated water and the pH was adjusted to 8.5 with 28% NH₄OH (solution A). K₃Fe(CN)₆ (1.75 g) was dissolved in 100 ml deoxygenated water and the pH was adjusted to 8.5 with 28% NH₄OH. This solution is called solution B.

Solution A was dropped into solution B in 2 hours and the mixture was allowed to stir 1 more hour. The pH was then adjusted to 4 with 10% AcOH and the solution was injected onto a prep.-HPLC. After purification a 28 mg peptide of 95% purity has been recovered.

The composition of the cyclic material was confirmed by analytical reverse phase HPLC and by Feb-35 MS. Typical HPLC chromatography is presented in Figure 3.

Example 4

Chemical Synthesis of Additional Peptides

40 Following the procedures outlined in Examples 1-3 and in Int. J. Pept. Proc. Res. 21, 57-65 (1983) with appropriate modification, the following peptides were synthesized. All peptides of the invention were tested for endotoxins using standard LAL assay procedures and found to be endotoxin free.

45

50

55

	1	CSVTCG (blocked cysteines)
	2	CSVTCR
5	2	CSVTCR-NH ₂
	2	CSVTCR
	3	CSTSCR
	3	CSTSCR-NH ₂
10	4	CSTSCG
	4	CSTSCG-NH ₂
	4	CSTSCG
15	4	CSTSCG (blocked cysteines)
	5	CRVTCG
	5	CRVTCG-NH ₂
20	5	CRVTC
	5	CRVTCG-NH ₂
	6	RCRVTCG
25	7	ASVTAR
	8	CSVTCK
	9	CSTSCK-NH ₂
30	10	CSRTCG
	10	CSRTCG-NH ₂
	11	CRTSCG-NH ₂
	12	CRVTC -NH ₂
35	13	CSTSC
	14	PCSVTCR-NH ₂
	14	PCSVTCR-NH ₂

40

Example 5Adhesion of Various Cells to TSP and Peptides

45

In this example a series of peptides were tested to determine the abilities of the peptides to bind various cells as compared to thrombospondin. It is believed that thrombospondin acts in metastasis through its adhesive properties. An assay was developed, generally in accordance with the disclosure of Tuszyński et al. (*Anal. Bio.* (1990) 184:189-91) which evaluates the ability of cells to adhere to the thrombospondin fragments or analogs of the invention. In this assay, thrombospondin (purified by the method of Tuszyński et al., *J. Biol. Chem.* (1985) 260:12240-5) served as a positive control, bovine serum albumin (BSA) (Sigma Chemical Co.) and the peptides ANKHYF and VCTGSC and TCVCGS served as negative controls. The cell types evaluated were B₁₆F₁₀ mouse melanoma cells, A549 human lung adenocarcinoma cells, bovine aortic smooth muscle cells, and rabbit smooth muscle cells.

55 Thrombospondin analogs of the invention were synthesized as described in Examples 1-4. Two micrograms of peptide or control proteins were air dried overnight on the wells of a 96-well microtiter plate. Wells were then washed with HEPES-buffered saline and blocked for 1 hour with 1% fatty acid free BSA in HEPES-buffered saline.

The various cells were grown and harvested during log phase of growth using standard procedures. The harvested cells were washed two times in serum-free Dulbecco's minimum essential medium (DMEM) (Flow Laboratories) and suspended in HEPES-buffered saline, containing 5 mM glucose and 100 μ M MgCl₂ at a final concentration of 4×10^5 cells/ml. Of the cell suspension 200,000 cells per well was added to each well 5 of the microtiter dish containing the various ligands and the dish incubated at 37°C in a CO₂ incubator for 30 minutes. Nonadherent cells were removed by aspiration and the wells washed three times with 200 μ l of PBS. The total cell-associated protein was determined by dissolving the attached cells directly in the microtiter wells with 200 μ l of the Pierce BCA working solution (Pierce Chem. Co. Booklet No. 23225 10 (1987)). The plate was covered with an adhesive mylar sheet (Flow Labs) and incubated at 60°C for 30 minutes. Plates were allowed to cool to room temperature, cover sheets were removed, and the absorbance of each well was determined at 562 nm with a microtiter plate reader (Biotek, Burlington, Vermont.) Absorbances were converted to number of adherent cells by means of an empirically determined conversion factor.

The results shown in Figure 4 graphically indicate that the peptides of the invention display adhesive properties to B₁₆F₀ melanoma cells. The results in Table II indicate that the peptides of the invention display adhesive activity on all tested cell lines.

TABLE II
Percent of TSP-adherent Cells
Cell Type

	Compound	B ₁₆ -F ₁₀ Mouse Melanoma	A549 Human Lung Adeno- carcinoma	Bovine Aortic Endothelia l Cells	Rabbit Smooth Muscle
20	ANKHYF	8	10	0	17
25	VCTGSC	2	8	3	17
30	TCVCGS	10	10	6	8
35	CSVTCG (SEQ ID NO:1)	40	29	49	44
40	Cyclic CSVTCG (SEQ ID NO:1)	30	29	25	43
45	Blocked CSVTCG (SEQ ID NO:1)	32	44	22	46
50	CSVTCR (SEQ ID NO:2)	92	90	99	159
55	CSTSCR (SEQ ID NO:3)	39	104	65	82
	CSTSCG (SEQ ID NO:4)	37	23	39	22
	CRVTCG (SEQ ID NO:5)	92	79	80	82
	ASVTAR (SEQ ID NO:7)	39	not tested	not tested	not tested

Example 6

The Effect of Peptides on Collagen Dependent Adhesion of B₁₀F₁₀ Melanoma Cells.

5 Two micrograms of collagen in 5 mM acetic acid were adsorbed to wells overnight at 4 °C. Wells were
then washed with HEPES-buffered saline and blocked for 1 hour with 1% fatty acid free bovine serum
albumin (BSA) in HEPES buffered saline. A suspension of B₁₆F₁₀ cells in HEPES-buffered saline,
containing 5 mM glucose (200,000 cells per well) and 100 µM MnCl₂ were preincubated for 15 minutes at
37 °C in either buffer or in buffer containing 100 µg/ml peptide or 100 µg/ml BSA. The cell suspensions
10 were then added to collagen-coated wells and incubated for 30 minutes at room temperature. Non-adherent
cells were removed by aspiration, and adherent cells determined by measurement of cell-associated protein
as previously described in Example 5. The results shown in Figure 5 indicate that the peptides of the
invention inhibit the binding of the melanoma cell to collagen.

15 Example 7

The Effect of Peptides on B₁₆F₁₀ Lung Tumor Cell Metastasis

The *in vivo* model used to demonstrate the antimetastatic activity of the peptide compounds of the invention is described by Tuszynski et al. (*Cancer Res.* (1987) 47:4130-4133). Briefly, C57 black mice were intravenously injected with 1×10^5 B₁₆F₁₀ mouse melanoma cells in the presence of either control buffer (Hepes buffered saline, pH 7.4), or 1 mg of the designated peptide compound of the invention. Five or six animals were used for each compound. Peptides tested in the assay had no effect on cell viability as measured by Trypan blue dye exclusion. In addition, the peptides at 1 mg/ml did not effect cell growth after 24 hours of co-culture. After 14 days, the mice were sacrificed and the number of lung tumors counted.

The results shown in Figure 6 indicate the peptides of the invention have antimetastatic activity. The bar graphs show the mean number of lung tumors observed in the treatment groups and the error bars represent the standard error of the mean. Figure 7 shows representative lungs from each of the treatment groups.

30

Platelet aggregation was monitored on a single-channel aggregometer equipped to measure luminescence (Chromo-Log, Havertown, Pennsylvania). Platelet-rich-plasma (PRP) was obtained from whole blood

The effect of peptides on ADP-induced platelet aggregation is shown in Figure 8. 0.5 ml aliquots of platelet-rich-plasma were aggregated by stirring with 2 uM ADP in the presence of various concentrations of CSVTCG and GRGDS. Aggregation was measured at 37°C as decrease in optical absorbance vs. time in a chrono-log aggregometer and is shown in Figure 8. Peptides designated in each panel are represented by their amino acid sequence using the one letter code.

Example 9

45

Washed human platelets were suspended in HEPES-buffered saline, containing 5 mM glucose and 350 µg/ml BSA. 0.5 ml aliquots of platelets were aggregated by stirring with 5 µg/ml collagen in the presence of 500 µg/ml of various peptides. Aggregation was measured at 37 °C as decrease in optical absorbance vs. time in a Chrono-log aggregometer and is shown in Figure 9. 100% aggregation was defined as the maximal decrease in absorbance measured in the absence of peptide. % of control was calculated as the decrease in absorbance measured in the presence of peptide divided by the decrease in absorbance measured in the absence of peptide times 100. Peptides are designated under each bar graph by their amino acid sequence represented using the one letter code.

Example 10

Dose-Response of CSVTCG on Collagen-Induced Platelet Aggregation.

Washed human platelets were suspended in HEPES-buffered saline, containing 5 mM glucose and 350 µg/ml BSA. 0.5 ml aliquots of platelets were aggregated by stirring with 5 µg/ml collagen in the presence of 5 various concentrations of CSVTCG (SEQ ID NO:1). Aggregation was measured at 37°C as decrease in optical absorbance vs. time in a chrono-log aggregometer and is shown in Figure 10. 100% aggregation was defined as the maximal decrease in absorbance measured in the absence of peptide. % of control was calculated as the decrease in absorbance measured in the presence of peptide divided by the decrease in absorbance measured in the absence of peptide times 100.

10

Example 11Adhesion of Human Platelets to TSP and Peptides.

15 The number of adherent platelets was essentially determined as previously described (Tuszynski et al., *Anal. Bio. supra*). Briefly, 100 µl of 5×10^8 platelets/ml washed as previously described (Tuszynski et al., (1988) *Blood* 72, 109-225) were added to microtiter plates, the wells of which were treated with 2 µg of 20 peptide or protein solution (HEPES buffered saline, pH 7.4). Solutions were dried at room temperature after incubation in a fume hood overnight. Wells were then washed with HEPES-buffered saline and blocked for 1 hour with 1% fatty acid free bovine serum albumin (BSA) in HEPES buffered saline. Platelets (100 µl) were 25 incubated in the wells for 30 minutes and non-adherent platelets were removed by aspiration. Wells were washed 3X with 200 µl of Hepes buffered saline, pH 7.4. The number of adherent platelets was determined by measuring the platelet-derived protein using the BCA protein assay. The results are shown in Figure 11. The label under each bar designates the protein or peptide used to coat the well. Proteins used were 30 thrombospondin (TSP), fibronectin (FN), and bovine serum albumin (BSA). Peptides are designated under each bar graph by their amino acid sequence represented using the one letter code. The peptide having blocked cys residues is given as C(x)SVTC(x)G-NH-2 (SEQ ID NO:1), where x represents the blocking group ACM. A suspension of platelets in Hepes-buffered saline, containing 5 mM glucose and 350 µg/ml BSA (5×10^7 platelets per well) were incubated in each well for 30 minutes, nonadherent platelets removed 35 by aspiration, and adherent cells determined by measurement of cell-associated protein as previously described (Tuszynski et al., (1990) 184:189-191). The data is a representative of 2-3 experiments and data points in each experiment are the mean of three determinations, and the error bars represent the standard error of the mean (SEM).

35

Example 12Capillary Endothelial Cell Proliferation Assay

40 The effect of the peptides of the invention on the proliferation of capillary endothelial cells *in vitro* were measured. Capillary endothelial cells are known to proliferate in response to angiogenic stimulus during neovascularization (Ausprunk et al., *J. Microrasc. Res.* (1977) 14:53). By using the specific cells involved in angiogenesis and stimulating them with a known angiogenesis factor, acidic fibroblast growth factor (aFGF), the angiogenesis process can be mimicked *in vitro*. The assay used was described by Moses et al. (Science 1990) 248:1408-10). Doses of 0.01, 0.1, 1.0, 10, and 100 µg/ml of the peptides of the invention 45 CSVTCG (SEQ ID NO:1) and CSVTCR (SEQ ID NO:2) were tested.

The most potent peptide was CSVTCR (SEQ ID NO:2) which showed 20% inhibition of stimulated endothelial cell proliferation at 10 µg/ml and 100% inhibition at 100 µg/ml. Peptide CSVTCG (SEQ ID NO:1) showed 39% inhibition at 100 µg/ml.

50

Example 13Collagenase Inhibition Assay

55 Collagenase has been shown to have a key role in the angiogenic process (Langer et al., *Proc. Natl. Acad. Sci.* (1980) 77:4331; Thurgiessson et al., *J. Natl. Cancer Inst.* (1982) 69:1049 and Rifkin et al. in *Pathology of the Endothelial Cell* (Academic Press, 1982) 191-197). Collagenase inhibitory activity was determined as described by Johnson-Wint (*Anal. Biochem.* (1980) 104:175). Peptides CSVTCG (SEQ ID NO:1) and CSVTCR (SEQ ID NO:2) were tested in the Johnson-Wint radiometric enzyme assay for

EP 0 478 101 A2

collagenase activity at doses of 50 ng, 100 ng, 250 ng, 500 ng, 1 µg and 2 µg.

Peptide CSVTCG (SEQ ID NO:1) was slightly inhibitory at 1 µg (-19%) and more inhibitory at 2 µg (-36%). Peptide CSVTCR (SEQ ID NO:2) was the most inhibitory at the lowest dose, -21% at 50 ng.

5 Example 14

Antibody Preparation

An antibody to CSTSCG (SEQ ID NO:4) was raised in a goat using standard protocols. Briefly, the 10 animal was injected with 1 mg of peptide coupled to keyhole limpet hemocyanin (KLH) emulsified in Freund's complete adjuvant, followed by two additional injections of 0.5 mg of coupled-peptide emulsified in incomplete Freund's adjuvant and administered three and six weeks after the first injection. The animal was subjected to plasmaphoresis twice and sacrificed. Plasma samples were pooled and serum prepared. Antibody was adsorbed with KLH-Sepharose to remove anti-KLH antibodies and affinity purified on a TSP-15 Sepharose column.

Affinity purified antibody crossreacted with TSP, CSTSCG coupled to bovine serum albumin (BSA), but not to fibrinogen or BSA alone. The antibody specifically inhibited TSP-induced melanoma cell adhesion. Negative controls were the following: No effect of anti-KLH antibody on TSP-mediated adhesion and no effect of anti-peptide antibody on fibronectin-induced adhesion.

20 This shows that CSTSCG (SEQ ID NO:4) is part of the cell adhesive domain of TSP.

Example 15

The Effect of Anti-CSTSCG (SEQ ID NO:4) on Platelet Aggregation

25 To further establish that the Type I repeats of TSP inhibit platelet aggregation, antibodies to CSTSCG (SEQ ID NO:4) were prepared as described in Example 14. The antibody was tested as described in Example 8.

Anti-CSTSCG at an affinity purified concentration range of 33-70 µg/ml inhibited ADP-induced human 30 platelet-rich-plasma as shown in Figure 12. However, 33-70 µg/ml of nonimmune control IgG purified by affinity chromatography showed no anti-aggregation properties.

This experiment provides further support that CSTSCG (SEQ ID NO:4) inhibits platelet aggregates.

Example 16

The Effect of Antibodies on Tumor Cell Metastasis

35 Antibodies to CSTSCG (SEQ ID NO:4) were prepared as described in Example 14, 100 µg of either control IgG or 100 µg of affinity purified anti-CSTSCG was coinjected with 1.0×10^5 B₁₆-F₁₀ mouse 40 melanoma cells into the interal tail vein of C57 black mice (6 mice per group) in a manner analogous to that described in Example 7. The melanoma cells were harvested in EDTA and suspended in Hepes-buffered saline solution pH-7.35 and antibodies dissolved in the same buffer.

Antibodies had no effect on the viability of the melanoma cells as assessed by trypan blue exclusion. Mice were sacrificed after two weeks and the lung tumor colonies counted.

45 Figure 13 shows that anti-CSTSCG inhibits tumor cell metastasis by 73-80%. This provides further support that CSVTCG is a cell domain in TSP and such peptide/antibodies have antitumor metastasis efficacy.

SEQUENCE LISTING

5

(1) GENERAL INFORMATION:

- (i) APPLICANT: Eyal, Jacob
Hamilton, Bruce King
Tuszynski, George Paul
- (ii) TITLE OF INVENTION: Therapeutic Use of Peptides Having Thrombospondin-like Activity
- (iii) NUMBER OF SEQUENCES: 14
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: W. R. Grace & Co.-Conn.
(B) STREET: 7379 Route 32
(C) CITY: Columbia
(D) STATE: Maryland
(E) COUNTRY: USA
(F) ZIP: 21044

- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Word Perfect 5.1
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION: 530

- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Appleby, Vanessa L.
(B) REGISTRATION NUMBER: 33223
(C) REFERENCE/DOCKET NUMBER: 01-7900

- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (301) 531-4515

- (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys Ser Val Thr Cys Gly
1 5

- (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids

EP 0 478 101 A2

- (B) TYPE: amino acid
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Cys Ser Val Thr Cys Arg
1 5
10

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Cys Ser Thr Ser Cys Arg
1 5
25

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Cys Ser Thr Ser Cys Gly
1 5
35

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Cys Arg Val Thr Cys Gly
1 5
45

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid

EP 0 478 101 A2

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Arg Cys Arg Val Thr Cys Gly
1 5

10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ala Ser Val Thr Ala Arg
1 5

25

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

35

Cys Ser Val Thr Cys Lys
1 5

40

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: peptide

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Cys Ser Thr Ser Cys Lys
1 5

55

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid

EP 0 478 101 A2

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Cys Ser Arg Thr Cys Gly
1 5

10

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

15

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Arg Thr Ser Cys Gly
1 5

25

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Cys Arg Val Thr Cys
1 5

40

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

50

Cys Ser Thr Ser Cys
1 5

55

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

10

Pro Cys Ser Val Thr Cys Arg
1 5

15 Claims

1. A method for promoting or inhibiting thrombospondin-like activity comprising administering an effective amount of a polypeptide compound comprising the formula:

20 R₁-X₁-X₂-X₃-X₄-X₅-R₂

wherein:

R₁ is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues or the desamino form thereof;

25 X₁ and X₅ are the same or different neutral/small amino acid residues;

X₂, X₃, and X₄ are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues;

30 R₂ is a protected or unprotected terminal carboxyl group including hydroxyl, carboxyl, or up to one hundred amino acid residues, including carboxamide or alkylamide forms thereof;

the structure of the polypeptide is optionally cyclized through a bond between X₁ and X₅ or a bond between R₁ and R₂.

- 35 2. The method of Claim 1 which inhibits cell adhesion.

3. The method of Claim 1 which inhibits platelet aggregation.

4. The method of Claim 2 which is useful for treating tumors.

- 40 5. The method of Claim 4 which inhibits tumor cell metastasis.

6. The method of Claim 4 which inhibits tumor growth.

- 45 7. The method of Claim 4 which reduces tumor size.

8. The method of Claim 4 which reduces tumor colony number.

9. The method of Claim 2 which inhibits angiogenesis.

- 50 10. The method of Claim 3 which is useful for preventing or treating thrombotic disorders.

11. The method of Claim 10 which is useful for preventing or treating cardiovascular disorders.

- 55 12. The method of Claim 11 which is used following angioplasty.

13. The method of Claim 10 which is useful for preventing or treating atherosclerosis.

14. The method of Claim 1 wherein:

R₁ is up to 20 amino acid residues;
 X₁ and X₅ are selected from the group consisting of cysteine, serine, and alanine;
 X₂, X₃, and X₄ are selected from the group consisting of valine, threonine, serine, and arginine;
 5 and
 R₂ is up to 20 amino acid residues.


15. The method of Claim 14 wherein the polypeptide compound is selected from the group consisting of:

10	CSVTCG	(SEQ ID NO:1)
	CSVTCR	(SEQ ID NO:2)
	CSTSCR	(SEQ ID NO:3)
15	CSTSCG	(SEQ ID NO:4)
	CRVTCG	(SEQ ID NO:5)
	RCRVTCG	(SEQ ID NO:6)
20	ASVTAR	(SEQ ID NO:7)
	CSVTCK	(SEQ ID NO:8)
	CSTSCK	(SEQ ID NO:9)
25	CSRTCG	(SEQ ID NO:10)
	CRTSCG	(SEQ ID NO:11)
	CRVTC	(SEQ ID NO:12)
	CSTSC	(SEQ ID NO:13)
30	PCSVTCSR	(SEQ ID NO:14)

wherein each peptide can include C-terminal acid and amide forms, disulfide linked forms and blocked cysteine forms.

35 16. The method of Claim 1 wherein said polypeptide compound is admixed with at least one pharmaceutically acceptable carrier prior to being administered.

40 17. A composition useful to inhibit thrombospondin-like activity comprising a pharmaceutically acceptable carrier together with an effective amount of a polypeptide compound comprising the formula:



45 wherein:

R₁ is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues or the desamino form thereof;
 X₁ and X₅ are the same or different neutral/small amino acid residues;
 X₂, X₃, and X₄ are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues;
 50 R₂ is a protected or unprotected terminal carboxyl group including hydroxyl, carboxyl, or up to one hundred amino acid residues, including carboxamide or alkylamide forms thereof;

55 the structure of the polypeptide is optionally cyclized through a bond between X₁ and X₅ or a bond between R₁ and R₂.

18. Antisera and antibodies which are capable of recognizing and specifically binding to an immunoreactive polypeptide comprising the formula:

$R_1-X_1-X_2-X_3-X_4-X_5-R_2$

wherein:

- 5 R_1 is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues or the desamino form thereof;
- X_1 and X_5 are the same or different neutral/small amino acid residues;
- X_2 , X_3 , and X_4 are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues;
- 10 R_2 is a protected or unprotected terminal carboxyl group including hydroxyl, carboxyl, or up to one hundred amino acid residues, including carboxamide or alkylamide forms thereof;
- 15 the structure of the polypeptide is optionally cyclized through a bond between X_1 and X_5 or a bond between R_1 and R_2 .

19. The antisera and antibodies of Claim 18 which are useful as diagnostics.
20. The antisera and antibodies of Claim 19 which are useful to diagnose cancer.
21. The antisera and antibodies of Claim 18 which are useful as therapeutics.
22. The antisera and antibodies of Claim 18 which provide effective removal of TSP from circulating fluids.
25. A method for facilitating the delivery of compounds to tumor cells for diagnostic or therapeutic purposes comprising the antisera and antibodies of Claim 18.
26. A method for facilitating the delivery of compounds to tumor cells for diagnostic or therapeutic purposes comprising a polypeptide compound comprising the formula:

30 $R_1-X_1-X_2-X_3-X_4-X_5-R_2$

wherein:

- 35 R_1 is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues or the desamino form thereof;
- X_1 and X_5 are the same or different neutral/small amino acid residues;
- X_2 , X_3 , and X_4 are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues;
- 40 R_2 is a protected or unprotected terminal carboxyl group including hydroxyl, carboxyl, or up to one hundred amino acid residues, including carboxamide or alkylamide forms thereof;
- 45 the structure of the polypeptide is optionally cyclized through a bond between X_1 and X_5 or a bond between R_1 and R_2 .

46. A biomedical device for promoting the attachment of tumor cells which incorporates a polypeptide compound comprising the formula:

50 $R_1-X_1-X_2-X_3-X_4-X_5-R_2$

wherein:

- 55 R_1 is a protected or unprotected terminal amino group, including hydrogen, amino, acetyl or up to one hundred amino acid residues or the desamino form thereof;
- X_1 and X_5 are the same or different neutral/small amino acid residues;
- X_2 , X_3 , and X_4 are the same or different neutral/non-polar/large/non-cyclic or neutral/polar/large/non-cyclic or neutral/polar/small or basic/non-cyclic amino acid residues;
- R_2 is a protected or unprotected terminal carboxyl group including hydroxyl, car-

EP 0 478 101 A2

boxyl, or up to one hundred amino acid residues, including carboxamide or alkylamide forms thereof;
the structure of the polypeptide is optionally cyclized through a bond between X₁ and X₅ or a bond between R₁ and R₂.

5

10

15

20

25

30

35

40


45

50

55

EP 0 478 101 A2

FIG. I



EP 0 478 101 A2

FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6






FIG. 7

FIG. 8





FIG. 9



EP 0 478 101 A2

FIG. 10




FIG. II




FIG. 12





FIG. 13





(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 478 101 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91250255.6

(51) Int. Cl.5: C07K 7/00, A61K 37/02,
C12P 21/00, G01N 33/53,
G01N 33/574, A61K 39/395

(22) Date of filing: 20.09.91

(30) Priority: 24.09.90 US 587197
13.09.91 US 757037

(43) Date of publication of application:
01.04.92 Bulletin 92/14

(84) Designated Contracting States:
DE FR GB IT

(88) Date of deferred publication of the search report:
03.03.93 Bulletin 93/09

(71) Applicant: W.R. Grace & Co.-Conn.
Grace Plaza, 1114 Ave. of the Americas
New York New York 10036(US)
Applicant: THE MEDICAL COLLEGE OF
PENNSYLVANIA
3300 Henry Avenue
Philadelphia, Pa. 19129(US)

(72) Inventor: Eyal, Jacob
1803 Autumn Frost Lane
Baltimore, MD 21209(US)
Inventor: Hamilton, Bruce King
15229 Watergate Road
Silver Spring, MD 20904(US)
Inventor: Tuszyński, George Paul
824 Thoreau Lane
Williamstown, NJ 08094(US)

(74) Representative: UEXKÜLL & STOLBERG
Patentanwälte
Beselerstrasse 4
W-2000 Hamburg 52 (DE)

(54) Therapeutic use of peptides having thrombospondin-like activity.

(57) Methods for using synthetic analogs of thrombospondin for potentiating or inhibiting thrombospondin-like activity are provided.

EP 0 478 101 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

EP 91 25 0255

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
X	WO-A-9 001 496 (RESEARCH EXPLOITATION LIMITED) 22 February 1990 * claims 1-34 *	17, 18	C07K7/00 A61K37/02 C12P21/00 G01N33/53 G01N33/574 A61K39/395
P, X	EP-A-0 443 404 (W.R. GRACE & CO.-CONN) 28 August 1991 * the whole document *	1-25	
P, X	SCIENCE vol. 249, 28 September 1990, AAAS, WASHINGTON, DC, US; pages 1574 - 1577 K.A. RICH ET AL. 'Cell-adhesive motif in region II of malarial circumsporozoite protein'	17, 18	

TECHNICAL FIELDS SEARCHED (Int. Cl. 5)

C07K
A61K
G01N
C12P

INCOMPLETE SEARCH

The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims

Claims searched completely :

Claims searched incompletely :

Claims not searched :

Reason for the limitation of the search:

see sheet C

Place of search	Date of completion of the search	Examiner
THE HAGUE	17 NOVEMBER 1992	HORNIG H.
CATEGORY OF CITED DOCUMENTS		
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		



Sheet C

EP 91250255

Remark:

As far as that claims 1-16, 23,24 are directed to a method of treatment of (diagnostic method practised on) the human/animal body (Article 52(4) EPC) the search has been carried out and is based on the alleged effects of the compound/composition.

